Leqvio FDA Approval
Despite availability of effective treatments, the burden of
cardiovascular disease on health systems is on the rise
CVD accounts for more deaths
than any other disease¹
% of deaths
US CVD costs to surpass
1 trillion p.a. by 20352
USD billion
Other
conditions
30%
Injuries
9%
Chronic
respiratory
diseases Diabetes
7%
2%
Cardiovascular
diseaseas
30%
Other
chronic
diseases
9%
Cancer
13%
555
2016
1,100
2035
30m patients with ASCVD in US5
900k lives lost to CVD annually
in the US³
After years of decline, number of
lives lost is rising again
14% of health expenditure due
to CVD, more than any major
diagnostic group6
CVD Cardiovascular Disease
ASCVD Atherosclerotic Cardiovascular Disease 1. Bloom, D.E., et al. (2011). The Global Economic Burden of Noncommunicable Diseases. Geneva: World Economic Forum. 2. Includes direct and
indirect costs. Source: AHA/ ASA Cardiovascular Disease: A costly burden for America. Projections through 2035. 3. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829-1830.
4. Virani SS,
et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8): e254-e743. Accessed July 17,2021. 5. Wong ND et al. J Clin Lipidol. 2016;10(5):1109-1118. 6. Virani SS et
al. Circulation. 2020;141(9):e139-e596. Note: The effect of Leqvio® on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials.
6
Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation
V NOVARTIS | Reimagining MedicineView entire presentation